IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Last trade$0.8781
Day change+$0.0621 (+7.61%)
Day range$0.764 – $0.882
Volume77,982
Market cap$9M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$8.86M
Price / earnings
—
Price / book
0.63×
Price / sales
—
EV / sales
—
EV / EBITDA
0.27×
Profitability
Earnings per share
-$1.80
Return on assets
-103.8%
Return on equity
-136.91%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.78×
Quick ratio
5.78×
Cash ratio
5.32×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$15M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for INAB, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.12M
$2.44M
$2.65M
$2.39M
$1.86M
$2.71M
$2.69M
$2.63M
Research and development
$2.6M
$2.49M
$2.61M
$2.65M
$2.1M
$2.49M
$2.97M
$3.59M
Total operating expenses
$4.72M
$4.94M
$5.27M
$5.03M
$3.97M
$5.2M
$5.66M
$6.22M
Operating income
-$4.72M
-$4.94M
-$5.27M
-$5.03M
-$3.97M
-$5.2M
-$5.66M
-$6.22M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$4.59M
-$4.78M
-$5.09M
-$4.94M
-$3.85M
-$5.09M
-$5.55M
-$6.16M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$4.59M
-$4.78M
-$5.09M
-$4.94M
-$3.85M
-$5.09M
-$5.55M
-$6.16M
Net income attributable to common shareholders
-$4.59M
-$4.78M
-$5.09M
-$4.94M
-$3.85M
-$5.09M
-$5.55M
-$6.16M
EBITDA
-$4.46M
-$4.68M
-$5.02M
-$4.79M
-$3.72M
-$4.95M
-$5.4M
-$5.97M
Basic earnings per share
-$0.24
-$0.25
-$0.26
-$0.79
-$0.85
-$1.24
-$2.16
-$2.41
Diluted earnings per share
-$0.24
-$0.25
-$0.26
-$0.79
-$0.85
-$1.24
-$2.16
-$2.41
Recent news
Company coverage with links to the original publishers.
IN8bio, Inc. (Nasdaq: INAB) announced that its Compensation Committee granted a new employee nonqualified stock options to purchase 60,000 shares of common stock as an inducement to join the company. The options vest over four years with 25% vesting on the first anniversary and the remainder in equal monthly installments thereafter.
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies, announced that CEO William Ho will present at the Sidoti Small-Cap Virtual Conference on September 24, 2026. The presentation will cover the company's differentiated γδ T cell platform and pipeline, including lead program INB-619 and clinical-stage oncology programs.
IN8bio announced peer-reviewed clinical results from its Phase 1 trial of INB-200 (DeltEx DRI) published in The Journal of Clinical Oncology. The chemotherapy-resistant gamma-delta T cell therapy demonstrated a median progression-free survival of 16.1 months in repeat-dose patients, more than double the standard of care benchmark of 6.9 months, with no dose-limiting toxicities. The therapy showed a well-tolerated safety profile and median overall survival of 19.5 months in repeat-dose patients.
IN8bio announced presentations at major medical conferences in May-June 2026, including new clinical data on its gamma-delta T cell therapies at ASCO. The company will host an R&D Day on May 21, 2026, showcasing advances in its T cell engager platform and clinical programs, particularly highlighting survival benefits observed in glioblastoma patients treated with DeltEx DRI.
IN8bio, Inc. (Nasdaq: INAB) announced that its Compensation Committee granted nonqualified stock options for 11,800 shares of common stock to two new employees on April 1, 2026, as an inducement for employment. The options will vest over four years with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.